Redox-active quinones and ascorbate: An innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 213-221

  Verrax, Julien ^a   Beck, Raphael ^a   Dejeans, Nicolas ^a   Glorieux, Christophe ^a   Sid, Brice ^a   Pedrosa, Rozangela C ^b   Benites, Julio ^c   Vásquez, David ^c,d   Valderrama, Jaime A ^c,d   Calderon, Pedro Buc ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSIDAD ARTURO PRAT   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Ascorbate; Cancer; Oxidative stress; Quinone; Redox cycling

Indexed keywords

2 METHOXYESTRADIOL; ADENOSINE TRIPHOSPHATE; ARSENIC TRIOXIDE; ASCORBIC ACID; BETA LAPACHONE; BLEOMYCIN; BUTHIONINE SULFOXIMINE; GADOLINIUM TEXAPHYRIN; ISOTHIOCYANIC ACID DERIVATIVE; PHENYLETHYLISOTHIOCYANATE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; ENZYME ACTIVITY; HUMAN; NEOPLASM; OXIDATION REDUCTION STATE; OXIDATIVE STRESS;

EID: 79953780625     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795255902     Document Type: Article

References (107)

1. 2 and vanadate stimulate protein tyrosine phosphorylation in intact-cells. J. Biol. Chem., 1990, 265(5), 2896-2902.
2. 2-mediated cell signaling. FEBS Lett., 2004, 560(1-3), 7-13.
3. Chan, E. C.; Jiang, F.; Peshavariya, H. M.; Dusting, G. J. Regulation of cell proliferation by NADPH oxidase-mediated signaling: Potential roles in tissue repair, regenerative medicine and tissue engineering. Pharmacol. Therapeut., 2009, 122(2), 97-108.
4. Foreman, J.; Demidchik, V.; Bothwell, J. H. F.; Mylona, P.; Miedema, H.; Torres, M. A.; Linstead, P.; Costa, S.; Brownlee, C.; Jones, J. D. G.; Davies, J. M.; Dolan, L. Reactive oxygen species produced by NADPH oxidase regulate plant cell growth. Nature, 2003, 422(6930), 442-446.
5. 2+ channel alpha(1c) subunits but does not mediate their sensitivity to acute hypoxia. Biochem. Bioph. Res. Co., 2004, 318(1), 135-141.
6. Hu, Q. H.; Yu, Z. X.; Ferrans, V. J.; Takeda, K.; Irani, K.; Ziegelstein, R. C. Critical role of NADPH oxidase-derived reactive oxygen species in generating Ca2+ oscillations in human aortic endothelial cells stimulated by histamine. J. Biol. Chem., 2002, 277(36), 32546-32551.
7. Schreck, R.; Rieber, P.; Baeuerle, P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J., 1991, 10(8), 2247-2258.
8. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P.; Achanta, G.; Arlinghaus, R.; Liu, J.; Huang, P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 2006, 10(3), 241-252.
9. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8(7), 579-591.
10. Sattler, M.; Verma, S.; Shrikhande, G.; Byrne, C.; Pride, Y.; Winkler, T.; Greenfield, E.; Salgia, R.; Griffin, J. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem., 2000, 275(32), 24273-24278.
11. Naughton, R.; Quiney, C.; Turner, S. D.; Cotter, T. G. Bcr-Ablmediated redox regulation of the PI3K/AKT pathway. Leukemia, 2009, 23(8), 1432-1440.
12. Koptyra, M.; Falinski, R.; Nowicki, M. O.; Stoklosa, T.; Majsterek, I.; Nieborowska-Skorska, M.; Blasiak, J.; Skorski, T. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 2006, 108(1), 319-327.
13. Lee, A. C.; Fenster, B. E.; Ito, H.; Takeda, K.; Bae, N. S.; Hirai, T.; Yu, Z. X.; Ferrans, V. J.; Howard, B. H.; Finkel, T. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem., 1999, 274(12), 7936-7940.
14. Vafa, O.; Wade, M.; Kern, S.; Beeche, M.; Pandita, T.; Hampton, G.; Wahl, G. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell, 2002, 9(5), 1031-1044.
15. Komatsu, D.; Kato, M.; Nakayama, J.; Miyagawa, S.; Kamata, T. NADPH oxidase 1 plays a critical mediating role in oncogenic Rasinduced vascular endothelial growth factor expression. Oncogene, 2008, 27(34), 4724-4732.
16. Kizaki, M.; Xian, M.; Sagawa, M.; Ikeda, Y. Induction of apoptosis via the modulation of reactive oxygen species (ROS) production in the treatment of myeloid leukemia. Curr. Pharm. Biotechnol., 2006, 7(5), 323-329.
17. Sanjuan-Pla, A.; Cervera, A. M.; Apostolova, N.; Garcia-Bou, R.; Victor, V. M.; Murphy, M. P.; McCreath, K. J. A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett., 2005, 579(12), 2669-2674.
18. Lim, S. D.; Sun, C.; Lambeth, J. D.; Marshall, F.; Amin, M.; Chung, L.; Petros, J. A.; Arnold, R. S. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate, 2005, 62(2), 200-207.
19. Wang, J.; Yi, J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther., 2008, 7(12), 1875-1884.
20. Ferraro, D.; Corso, S.; Fasano, E.; Panieri, E.; Santangelo, R.; Borrello, S.; Giordano, S.; Pani, G.; Galeotti, T. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene, 2006, 25(26), 3689-3698.
21. Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; Nakada, K.; Honma, Y.; Hayashi, J. ROS generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 2008, 320(5876), 661-664.
22. Weydert, C. J.; Waugh, T. A.; Ritchie, J. M.; Iyer, K. S.; Smith, J. L.; Li, L.; Spitz, D. R.; Oberley, L. W. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic. Biol. Med., 2006, 41(2), 226-237.
23. Verrax, J.; Cadrobbi, J.; Marques, C.; Taper, H.; Habraken, Y.; Piette, J.; Calderon, P. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 2004, 9(2), 223-233.
24. Sanchez, M.; Torres, J. V.; Tormos, C.; Iradi, A.; Muniz, P.; Espinosa, O.; Salvador, A.; Rodriguez-Delgado, J.; Fandos, M.; Saez, G. T. Impairment of antioxidant enzymes, lipid peroxidation and 8-oxo-2'-deoxyguanosine in advanced epithelial ovarian carcinoma of a Spanish community. Cancer Lett., 2006, 233(1), 28-35.
25. Kinnula, V.; Crapo, J. Superoxide dismutases in malignant cells and human tumors. Free Radic. Biol. Med., 2004, 36(6), 718-744.
26. Sander, C. S.; Hamm, F.; Elsner, P.; Thiele, J. J. Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br. J. Dermatol., 2003, 148(5), 913-922.
27. Monari, M.; Foschi, J.; Calabrese, C.; Liguori, G.; Di Febo, G.; Rizzello, F.; Gionchetti, P.; Trinchero, A.; Serrazanetti, G. P. Implications of antioxidant enzymes in human gastric neoplasms. Int. J. Mol. Med., 2009, 24(5), 693-700.
28. Hwang, T. S.; Choi, H. K.; Han, H. S. Differential expression of manganese superoxide dismutase, copper/zinc superoxide dismutase, and catalase in gastric adenocarcinoma and normal gastric mucosa. Eur. J. Surg. Oncol., 2007, 33(4), 474-479.
29. Sato, K.; Ito, K.; Kohara, H.; Yamaguchi, Y.; Adachi, K.; Endo, H. Negative regulation of catalase gene expression in hepatoma cells. Mol. Cell. Biol., 1992, 12(6), 2525-2533.
30. Verrax, J.; Pedrosa, R.; Beck, R.; Dejeans, N.; Taper, H.; Calderon, P. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr. Med. Chem., 2009, 16(15), 1821-1830.
31. Beck, R.; Pedrosa, R. C.; Dejeans, N.; Glorieux, C.; Leveque, P.; Gallez, B.; Taper, H.; Eeckhoudt, S.; Knoops, L.; Calderon, P. B.; Verrax, J. Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest. New Drugs, 2010.
32. Sun, Y.; Oberley, L.; Elwell, J.; Sierra-Rivera, E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int. J. Cancer, 1989, 44(6), 1028-1033.
33. Pljesa-Ercegovac, M.; Mimic-Oka, J.; Dragicevic, D.; Savic-Radojevic, A.; Opacic, M.; Pljesa, S.; Radosavljevic, R.; Simic, T. Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes. Urol. Oncol., 2008, 26(2), 175-181.
34. Rainis, T.; Maor, I.; Lanir, A.; Shnizer, S.; Lavy, A. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig. Dis. Sci., 2007, 52(2), 526-530.
35. Zelen, I.; Djurdjevic, P.; Popovic, S.; Stojanovic, M.; Jakovljevic, V.; Radivojevic, S.; Baskic, D.; Arsenijevic, N. Antioxidant enzymes activities and plasma levels of oxidative stress markers in Bchronic lymphocytic leukemia patients. J. BUON, 2010, 15(2), 330-336.
36. Lincoln, D. T.; Ali Emadi, E. M.; Tonissen, K. F.; Clarke, F. M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res., 2003, 23(3B), 2425-2433.
37. Biaglow, J. E.; Miller, R. A. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther., 2005, 4(1), 6-13.
38. Shan, W.; Zhong, W.; Zhao, R.; Oberley, T. D. Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic. Biol. Med., 2010, 49(12), 2078-2087.
39. Yanagawa, T.; Iwasa, S.; Ishii, T.; Tabuchi, K.; Yusa, H.; Onizawa, K.; Omura, K.; Harada, H.; Suzuki, H.; Yoshida, H. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett., 2000, 156(1), 27-35.
40. Noh, D. Y.; Ahn, S. J.; Lee, R. A.; Kim, S. W.; Park, I. A.; Chae, H. Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res., 2001, 21(3B), 2085-2090.
41. Chang, J. W.; Jeon, H. B.; Lee, J. H.; Yoo, J. S.; Chun, J. S.; Kim, J. H.; Yoo, Y. J. Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun., 2001, 289(2), 507-512.
42. Kinnula, V. L.; Lehtonen, S.; Sormunen, R.; Kaarteenaho-Wiik, R.; Kang, S. W.; Rhee, S. G.; Soini, Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol., 2002, 196(3), 316-323.
43. Cha, M. K.; Kim, I. H. Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma. Cancer Epidemiol., 2009, 33(3-4), 281-287.
44. Singh, S. V.; Brunnert, S. R.; Roberts, B.; Krishan, A. Differential expression of glutathione S-transferase, glutathione peroxidase and glutathione reductase in normal and malignant human breast tissues. Cancer Lett., 1990, 51(1), 43-48.
45. Peters, W. H.; Nagengast, F. M.; Wobbes, T. Glutathione Stransferases in normal and cancerous human colon tissue. Carcinogenesis, 1989, 10(12), 2371-2374.
46. Tsuchida, S.; Sekine, Y.; Shineha, R.; Nishihira, T.; Sato, K. Elevation of the placental glutathione S-transferase form (GST-pi) in tumor tissues and the levels in sera of patients with cancer. Cancer Res., 1989, 49(18), 5225-5229.
47. Cheng, Y.; Li, J.; Martinka, M.; Li, G. The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NFkappaB p105/p50 in human cutaneous melanomas. Oncol. Rep., 2010, 23(4), 973-979.
48. Marjani, H. A.; Biramijamal, F.; Rakhshani, N.; Hossein-Nezhad, A.; Malekzadeh, R. Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A casecontrol study from Iran. Genet. Mol. Res., 2010, 9(1), 239-249.
49. Bruge, F.; Virgili, S.; Cacciamani, T.; Principi, F.; Tiano, L.; Littarru, G. P. NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt's lymphoma cell lines. Biofactors, 2008, 32(1-4), 71-81.
50. Russo, A.; DeGraff, W.; Friedman, N.; Mitchell, J. B. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res., 1986, 46(6), 2845-2848.
51. Perry, R. R.; Mazetta, J. A.; Levin, M.; Barranco, S. C. Glutathione levels and variability in breast tumors and normal tissue. Cancer, 1993, 72(3), 783-787.
52. Lee, F. Y.; Allalunis-Turner, M. J.; Siemann, D. W. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br. J. Cancer, 1987, 56(1), 33-38.
53. Sakhi, A. K.; Russnes, K. M.; Thoresen, M.; Bastani, N. E.; Karlsen, A.; Smeland, S.; Blomhoff, R. Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study. B.M.C. Cancer, 2009, 9, 458.
54. Ito, Y.; Gajalakshmi, K. C.; Sasaki, R.; Suzuki, K.; Shanta, V. A study on serum carotenoid levels in breast cancer patients of Indian women in Chennai (Madras), India. J. Epidemiol., 1999, 9(5), 306-314.
55. Palan, P. R.; Mikhail, M. S.; Goldberg, G. L.; Basu, J.; Runowicz, C. D.; Romney, S. L. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha-and tau-tocopherol in cervical intraepithelial neoplasia and cancer. Clin. Cancer Res., 1996, 2(1), 181-185.
56. Venkitaraman, R.; Thomas, K.; Grace, P.; Dearnaley, D. P.; Horwich, A.; Huddart, R. A.; Parker, C. C. Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance. Tumour Biol., 2010, 31(2), 97-102.
57. Yeum, K. J.; Ahn, S. H.; Rupp de Paiva, S. A.; Lee-Kim, Y. C.; Krinsky, N. I.; Russell, R. M. Correlation between carotenoid concentrations in serum and normal breast adipose tissue of women with benign breast tumor or breast cancer. J. Nutr., 1998, 128(11), 1920-1926.
58. Head, K. A. Ascorbic acid in the prevention and treatment of cancer. Altern. Med. Rev., 1998, 3(3), 174-186.
59. Mayland, C.; Bennett, M.; Allan, K. Vitamin C deficiency in cancer patients. Palliat. Med., 2005, 19(1), 17-20.
60. Georgiannos, S.; Weston, P.; Goode, A. Micronutrients in gastrointestinal cancer. Br. J. Cancer, 1993, 68(6), 1195-1198.
61. Langemann, H.; Torhorst, J.; Kabiersch, A.; Krenger, W.; Honegger, C. Quantitative determination of water-and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int. J. Cancer, 1989, 43(6), 1169-1173.
62. Gatenby, R.; Gillies, R. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4(11), 891-899.
63. Agus, D.; Vera, J.; Golde, D. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., 1999, 59(18), 4555-4558.
64. Landolt, H.; Langemann, H.; Probst, A.; Gratzl, O. Levels of watersoluble antioxidants in astrocytoma and in adjacent tumor-free tissue. J. Neurooncol., 1994, 21(2), 127-133.
65. Kuiper, C.; Molenaar, I. G.; Dachs, G. U.; Currie, M. J.; Sykes, P. H.; Vissers, M. C. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res., 2010, 70(14), 5749-5758.
66. Pelicano, H.; Feng, L.; Zhou, Y.; Carew, J. S.; Hileman, E. O.; Plunkett, W.; Keating, M. J.; Huang, P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem., 2003, 278(39), 37832-37839.
67. Lu, J.; Chew, E. H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U S A, 2007, 104(30), 12288-12293.
68. Griffith, O. W.; Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem., 1979, 254(16), 7558-7560.
69. Lo, M.; Wang, Y. Z.; Gout, P. W. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol., 2008, 215(3), 593-602.
70. Le, S. B.; Hailer, M. K.; Buhrow, S.; Wang, Q.; Flatten, K.; Pediaditakis, P.; Bible, K. C.; Lewis, L. D.; Sausville, E. A.; Pang, Y. P.; Ames, M. M.; Lemasters, J. J.; Holmuhamedov, E. L.; Kaufmann, S. H. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J. Biol. Chem., 2007, 282(12), 8860-8872.
71. May, J. M. Is ascorbic acid an antioxidant for the plasma membrane? FASEB J., 1999, 13(9), 995-1006.
72. Carr, A.; Frei, B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J., 1999, 13(9), 1007-1024.
73. Calderon, P.B.; Cadrobbi, J.; Marques, C.; Hong-Ngoc, N.; Jamison, J.M.; Gilloteaux, J.; Summers, J.L.; Taper, H.S. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr. Med. Chem., 2002, 9(24), 2271-2285.
74. Taper, H.; de Gerlache, J.; Lans, M.; Roberfroid, M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int. J. Cancer, 1987, 40(4), 575-579.
75. Noto, V.; Taper, H.; Jiang, Y.; Janssens, J.; Bonte, J.; De Loecker, W. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer, 1989, 63(5), 901-906.
76. Taper, H.; Keyeux, A.; Roberfroid, M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res., 1996, 16(1), 499-503.
77. Verrax, J.; Calderon, P. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic. Biol. Med., 2009, 47(1), 32-40.
78. Hoffer, L.; Levine, M.; Assouline, S.; Melnychuk, D.; Paddayatty, S.; Rosadiuk, K.; Rousseau, C.; Robitaille, L.; Miller, W. J. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann. Oncol., 2008, 19(11), 1969-1974.
79. Verrax, J.; Delvaux, M.; Beghein, N.; Taper, H.; Gallez, B.; Buc Calderon, P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic. Res., 2005, 39(6), 649-657.
80. Verrax, J.; Stockis, J.; Tison, A.; Taper, H.; Calderon, P. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem. Pharmacol., 2006, 72(6), 671-680.
81. Verrax, J.; Vanbever, S.; Stockis, J.; Taper, H.; Calderon, P. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadioneinduced oxidative stress in K562 human chronic myelogenous leukemic cells. Int. J. Cancer, 2007, 120(6), 1192-1197.
82. Dejeans, N.; Tajeddine, N.; Beck, R.; Verrax, J.; Taper, H.; Gailly, P.; Calderon, P. B. Endoplasmic reticulum calcium release potentiates the ER stress and cell death caused by an oxidative stress in MCF-7 cells. Biochem. Pharmacol., 2010, 79(9), 1221-1230.
83. Beck, R.; Verrax, J.; Dejeans, N.; Taper, H.; Buc Calderon, P. Menadione reduction by pharmacological doses of ascorbate induces an oxidative stress that kills breast cancer cells. Int. J. Toxicol., 2009, 28(1), 33-42.
84. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26(22), 3279-3290.
85. Beck, R.; Verrax, J.; Gonze, T.; Zappone, M.; Pedrosa, R.; Taper, H.; Feron, O.; Calderon, P. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem. Pharmacol., 2009, 77(3), 375-383.
86. Tareen, B.; Summers, J.; Jamison, J.; Neal, D.; McGuire, K.; Gerson, L.; Diokno, A. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int. J. Med. Sci., 2008, 5(2), 62-67.
87. Levine, M.; Conry-Cantilena, C.; Wang, Y.; Welch, R.; Washko, P.; Dhariwal, K.; Park, J.; Lazarev, A.; Graumlich, J.; King, J.; Cantilena, L. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. U S A, 1996, 93(8), 3704-3709.
88. Levine, M.; Wang, Y.; Padayatty, S.; Morrow, J. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. U S A, 2001, 98(17), 9842-9846.
89. Chen, Q.; Espey, M.; Sun, A.; Lee, J.; Krishna, M.; Shacter, E.; Choyke, P.; Pooput, C.; Kirk, K.; Buettner, G.; Levine, M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. U S A, 2007, 104(21), 8749-8754.
90. Rees, D.; Kelsey, H.; Richards, J. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. B.M.J., 1993, 306(6881), 841-842.
91. Peña de la Vega, L.; Lieske, J.; Milliner, D.; Gonyea, J.; Kelly, D. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J. Parenter. Enteral. Nutr., 2004, 28(6), 435-438.
92. Massey, L.; Liebman, M.; Kynast-Gales, S. Ascorbate increases human oxaluria and kidney stone risk. J. Nutr., 2005, 135(7), 1673-1677.
93. Margolin, K. A.; Akman, S. A.; Leong, L. A.; Morgan, R. J.; Somlo, G.; Raschko, J. W.; Ahn, C.; Doroshow, J. H. Phase I study of mitomycin C and menadione in advanced solid tumors. Cancer Chemother. Pharmacol., 1995, 36(4), 293-298.
94. Tetef, M.; Margolin, K.; Ahn, C.; Akman, S.; Chow, W.; Leong, L.; Morgan, R. J., Jr.; Raschko, J.; Somlo, G.; Doroshow, J. H. Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest. New Drugs, 1995, 13(2), 157-162.
95. Lim, D.; Morgan, R. J., Jr.; Akman, S.; Margolin, K.; Carr, B. I.; Leong, L.; Odujinrin, O.; Doroshow, J. H. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New Drugs, 2005, 23(3), 235-239.
96. Matsumoto, S. S.; Biggs, J.; Copp, B. R.; Holden, J. A.; Barrows, L. R. Mechanism of ascididemin-induced cytotoxicity. Chem. Res. Toxicol., 2003, 16(2), 113-122.
97. Benites, J.; Rojo, L.; Valderrama, J. A.; Taper, H.; Calderon, P. B. Part 1: Effect of vitamin C on the biological activity of two euryfurylbenzoquinones on TLT, a murine hepatoma cell line. Eur. J. Med. Chem., 2008, 43(9), 1813-1817.
98. Valderrama, J. A.; Benites, J.; Cortes, M.; Pessoa-Mahana, D.; Prina, E.; Fournet, A. Studies on quinones. Part 35: Access to antiprotozoal active euryfurylquinones and hydroquinones. Tetrahedron, 2002, 58(5), 881-886.
99. Valderrama, J. A.; Benites, J.; Cortes, M.; Pessoa-Mahana, H.; Prina, E.; Fournet, A. Studies on quinones. Part 38: Synthesis and leishmanicidal activity of sesquiterpene 1,4-quinones. Bioorg. Med. Chem., 2003, 11(22), 4713-4718.
100. Benites, J.; Valderrama, J. A.; Taper, H.; Buc Calderon, P. Part 2: influence of 2-euryfuryl-1,4-naphthoquinone and its peri-hydroxy derivatives on both cell death and metabolism of TLT cells, a murine hepatoma cell line. modulation of cytotoxicity by vitamin C. Chem. Pharm. Bull. (Tokyo), 2009, 57(6), 615-619.
101. Vasquez, D.; Rodriguez, J. A.; Theoduloz, C.; Verrax, J.; Calderon, P. B.; Valderrama, J. A. Synthesis and antitumor evaluation of 8-phenylaminopyrimido [4,5-c]isoquinolinequinones. Bioorg. Med. Chem. Lett., 2009, 19(17), 5060-5062.
102. Valderrama, J. A.; Ibacache, J. A.; Arancibia, V.; Rodriguez, J.; Theoduloz, C. Studies on quinones. Part 45: Novel 7-aminoisoquinoline-5,8-quinone derivatives with antitumor properties on cancer cell lines. Bioorg. Med. Chem., 2009, 17(7), 2894-2901.
103. Valderrama, J. A.; Ibacache, J. A. Regiochemical control in the amination reaction of phenanthridine-7,10-quinones. Tetrahedron Lett., 2009, 50(30), 4361-4363.
104. Vasquez, D.; Rodriguez, J. A.; Theoduloz, C.; Calderon, P. B.; Valderrama, J. A. Studies on quinones. Part 46. Synthesis and in vitro antitumor evaluation of aminopyrimidoisoquinolinequinones. E. J. Med. Chem., 2010, 45(11), 5234-5242.
105. Roginsky, VA.; Barsukova, T.K.; Stegmann, H.B. Kinetics of redox interaction between substituted quinones and ascorbate under aerobic conditions. Chem. Biol. Interact., 1999, 121(2), 177-197.
106. Song, Y.; Buettner, G.R. Thermodynamic and kinetic considerations for the reaction of semiquinone radicals to form superoxide and hydrogen peroxide. Free Radic. Biol. Med., 2010, 49(6), 919-962.
107. Jarabak, R.; Jarabak, J. Effect of ascorbate on DT-diaphorasemediated redox cycling of 2-methyl-1,4-naphthoquinone. Arch. Biochem. Biophys., 1995, 318(2), 418-423.